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Abstract
Context: Gastrointestinal and pancreatic (GIP) endocrine tumors (ETs) have been regarded as
slow growing neoplasms with distinct morphologic characteristics that behave less aggressively
than carcinomas. The malignant potential of these tumors is difficult to predict.
Objective: To evaluate prognostic parameters, namely tumor size, tumor grade, and Ki-67 index
in relationship to metastatic behavior of GIP ETs.
Design: Biopsies and surgical specimens from 38 patients with GIP ETs were selected. The study
group comprised 16 males and 22 females (mean age 62.6 years; range 24–91). Formalin-fixed,
paraffin-embedded tissue sections were stained with H&E, synaptophysin, chromogranin A, and Ki-
67. Ki-67 index was evaluated using ChromaVision Automated Assisted Image Analysis software.
Proliferative index was compared to tumor grade, and the degree of associations between tumor
size, tumor grade, Ki-67 index and metastatic behavior of GIP ETs were evaluated.
Results: Fifteen of the twenty-two (68.18%) surgically staged neoplasms presented with peritoneal
dissemination, lymphogeneous, and/or hematogeneous metastases. Nine of the metastatic tumors
were G1 (9/13, or 69.23%), 5 were G2 (5/7, or 71.42%), and 1 – G3 (1/2, or 50%). Overall, 10/15
(66.66%) metastatic tumors showed < 2% Ki-67 immunoreactivity. Four ileal ETs had a
synchronous malignancy. No significant correlation was found to exist between tumor grade and
Ki-67 index as well as between tumor size, tumor grade, Ki-67 index and metastatic behavior.
Conclusion: The findings suggest that tumor size, tumor grade and Ki-67 index do not accurately
predict malignant behavior of GIP ETs.
Background
For many years, tumors of the disseminated endocrine
system have been referred as "carcinoids" [1-3]. Obern-
dorfer coined this term in 1907 for these epithelial tumors
in the gut that in general have a relatively monotonous
structure and are less aggressive in their behavior than car-
cinomas [1-6]. Factors that determine the biologic behav-
ior of endocrine tumors are complex and multifaceted. In
the WHO classification of 2000, a distinction was made
between well-differentiated endocrine tumors (which
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show benign behavior or uncertain malignant potential),
well-differentiated endocrine carcinomas (which are char-
acterized by less aggressive malignant behavior), and
poorly differentiated endocrine carcinomas of high-grade
malignancy [5-10]. However, the reproducibility of this
grading system and its prognostic importance has some-
Table 1: Distribution of GIP ETs*
Location Number of cases Number of cases with metastatic disease
Stomach 3 0
Duodenum/upper jejunum 10 3/4**
Distal jejunum/ileum 10 7/9**
Appendix 2 0/2**
Colon 4 2/3**
Rectum 5 0
Pancreas 4 3/4**
* Gatrointestinal and pancreatic (GIP) endocrine tumors (ETs)
** Surgically staged tumors
Table 2: Clinicopathologic data in GIP ETs*
Case No. Location Size Grade Ki-67 Metastases
1 Ileum 2.1 cm G1 8% Yes
2 Colon 11 cm G3 55% No
3 Colon 2.9 cm G2 3% Yes
4 Appendix 0.3 cm G1 1% No
5 Duodenum N/A G1 33% N/A
6 Duodenum N/A G1 4% N/A
7 Duodenum 1.3 cm G2 4% Yes
8 Pancreas 1.9 cm G2 2% Yes
9 Stomach N/A G1 6% N/A
10 Duodenum N/A G1 1% N/A
11 Colon 3.5 cm G2 0% Yes
12 Rectum N/A G1 0% N/A
13 Duodenum 2.5 cm G1 0% Yes
14 Duodenum N/A G1 0% N/A
15 Duodenum N/A G1 3% N/A
16 Rectum N/A G1 0% N/A
17 Rectum N/A G1 0% N/A
18 Colon N/A G1 0% N/A
19 Stomach N/A G1 3% N/A
20 Duodenum N/A G1 1% N/A
21 Ileum 1.3 cm G1 3% No
22 Ileum N/A G1 1% N/A
23 Ileum 0.9 cm G1 0% Yes
24 Stomach N/A G1 2% N/A
25 Ileum 3.0 cm G1 0% Yes
26 Rectum N/A G1 1% N/A
27 Ileum 0.7 cm G1 1% Yes
28 Duodenum N/A G1 3% N/A
9 Pancreas 16 cm G3 32% Yes
30 Pancreas 4.1 cm G2 2% No
31 Ileum 1.4 cm G1 1% No
32 Ileum 2.4 cm G1 0% Yes
33 Duodenum 1.5 cm G2 4% No
34 Pancreas 2.8 cm G1 3% Yes
35 Duodenum 4 cm G2 1% Yes
36 Ileum 1.2 cm G1 2% Yes
37 Ileum 2.5 cm G1 0% Yes
38 Appendix 1 cm G1 6% No
* Gastrointestinal and pancreatic (GIP) endocrine tumors (ETs)Diagnostic Pathology 2007, 2:28 http://www.diagnosticpathology.org/content/2/1/28
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times been called into question [8]. In endocrine tumors,
a number of clinicopathologic criteria proved to be useful
predictors of malignant behavior; these include: site of
origin; tumor type; tumor size; invasion of nearby tissue
or deep wall invasion; angioinvasion and invasion of
perineural spaces; presence of spotty necrosis; overt cellu-
lar atypia; more than two mitoses in 10 HPFs; Ki-67 index
of more than 100/10 HPFs, or more than 2%; loss of
chromogranin A immunoreactivity; and nuclear p53 accu-
mulation [4-23]. However, the predictive value of such
variables remains to be proven for tumors other than
those of pancreas and stomach [6].
The objective of our study is to investigate the potential
utility of cell proliferation (Ki-67 index) and histopatho-
logic grading in augmenting the histological classification
and assessing biologic aggressiveness in biopsies and sur-
gical specimens with gastrointestinal and pancreatic (GIP)
endocrine tumors (ETs).
Methods
Specimens
Thirty eight patients (22 women and 16 men, age range,
24–91 years, mean 62.4) were diagnosed as having a GIP
ET (Table 1) at our institution between 2003 and 2005.
Material was obtained from formalin-fixed, biopsies (n =
16) or resection specimens (n = 22). Hematoxylin-eosin-
stained sections were available for review in all cases. The
use of paraffin blocks for this study meets Institutional
Review Board and Health Insurance Portability and
Accountability Act requirements, and has been approved
by the Institutional Review Board at the University of Mar-
yland.
Classification and histopathologic grading
The tumors were classified according to the World Health
Organization guidelines [5]. Histopathologic grading was
performed according to the previously published criteria
[5,7,8]. Briefly, grade 1 (G1) ETs were characterized by a
variable structure, either with insular, trabecular, acinar,
diffuse or mixed patterns, and by a monomorphic cytol-
ogy with low atypia and rare if any mitosis (< 2/10 HPFs).
Grade 2 (G2) ETs showed focal moderate cytologic atypia
with few scattered mitotic figures (2–10/10 HPFs) and
spotty necrosis. Grade 3 (G3) ETs demonstrated a solid
growth pattern; the tumor cells were small, round, or oat-
cell-like with marked nuclear pleomorphism, brisk
mitotic activity (> 10/10 HPFs) and sizable areas of tumor
necrosis.
Table 3: Correlation between tumor grade and metastatic disease
Grade Metastases (+) Metastases (-) Total
G1 9 4 13
G2 5 2 7
G3 1 1 2
Total 15 7 22
Degrees of freedom: 2
Chi-square = 0.345368916797488
For significance at the .05 level, chi-square should be greater than or equal to 5.99.
The distribution is not significant.
p is less than or equal to 1.
Table 4: Correlation between tumor grade and Ki-67 index
Grade Ki-67 Index > 2% Ki-67 Index < 2% Total
G1 10 19 29
G2 3 4 7
G3 2 0 2
Total 15 23 38
* Cases with Ki-67 index of 2% were included in the < 2% category.
Degrees of freedom: 2
Chi-square = 3.40255586492468
For significance at the .05 level, chi-square should be greater than or equal to 5.99.
The distribution is not significant.
p is less than or equal to 0.20.Diagnostic Pathology 2007, 2:28 http://www.diagnosticpathology.org/content/2/1/28
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Immunohistochemical analysis
Immunostaining was performed according to the manu-
facturer's specifications. Briefly, four micron-thin sections
were placed on the VentanaNexES autostainer (Ventana
Medical Systems Inc, Tucson, Arizona) where they were
treated with protease for 4 minutes and then incubated
with prediluted anti-Ki-67 (Ventana, MM1, mouse mono-
clonal), anti-synaptophysin (CellMarque, rabbit polyclo-
nal), and anti-chromogranin A (Ventana, LKZH10, mouse
monoclonal) for 32 minutes. Recommended positive and
negative controls were used. Visualization was performed
using Ventana enhanced DAB detection kit. Ki-67 (MM1)
stained slides were evaluated using ChromaVision Auto-
mated Quantitative Image Analysis software (objective, ×
40). All tumor cell areas on the slide that stained posi-
tively were included as part of the evaluations regardless
of the degree of staining. Cases with Ki-67 immunoreac-
tivity of less than 1% were scored "0".
Statistical analysis
The chi-square test was used to test the association
between tumor grade and Ki-67 index as well as between
tumor grade, tumor size, Ki-67 index and metastatic
behavior of GIP ETs.
Results
Of the 38 endocrine tumors, 29 were G1, 7 were G2, and
2 – G3. Fifteen of the twenty-two (68.18%) surgically
staged neoplasms presented with peritoneal dissemina-
tion, lymphogeneous, and/or hematogeneous metastases
(Table 2).
Nine of the metastatic tumors were G1 (9/13, or 69.23%),
5 were G2 (5/7, or 71.42%), and 1 – G3 (1/2, or 50%)
(Table 3). Unexpectedly high association with metastasis
was found in small (< 2 cm), G1, endocrine tumors (Table
2). The results of the automated quantitative Ki-67 immu-
noreactivity analysis in comparison to tumor grade and
metastatic disease are shown in Tables 4 and 5. Overall,
10/15 (66.66%) metastatic tumors showed < 2% Ki-67
immunoreactivity (Figs. 1, 2, 3, 4, 5, 6). On the other
hand, non-metastatic G1-3 ETs demonstrated a high Ki-67
index (Figs. 7 and 8) (Table 2). No statistically significant
correlation was found to exist between tumor grade,
tumor size, Ki-67 index and metastatic behavior (Tables 3,
5 and 6).
Four of the 22 surgically staged GIP ETs had a synchro-
nous malignancy: one non-metastatic ileal ET with syn-
chronous non-metastatic colon adenocarcinoma, and
three metastatic ileal ETs with synchronous metastatic
colon and common bile duct adenocarcinomas, and non-
Table 5: Correlation between Ki-67% index and metastatic disease
Ki-67 Index Metastases (+) Metastases (-) Total
> 2% 5 4 9
< 2%* 10 3 13
Total 15 7 22
* Cases with Ki-67 index of 2% were included in the < 2% category.
Degrees of freedom: 1
Chi-square = 1.11925111925112
For significance at the .05 level, chi-square should be greater than or equal to 3.84.
The distribution is not significant.
p is less than or equal to 1.
Table 6: Correlation between tumor size and metastatic disease
Size Metastases (+) Metastases (-) Total
< 2 cm* 5 5 10
> 2 cm 10 2 12
Total 15 7 22
* Tumors measuring 2 cm were includes in < 2 cm category.
Degrees of freedom: 1
Chi-square = 2.79365079365079
For significance at the .05 level, chi-square should be greater than or equal to 3.84.
The distribution is not significant.
p is less than or equal to 0.10.Diagnostic Pathology 2007, 2:28 http://www.diagnosticpathology.org/content/2/1/28
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metastatic renal cell papillary carcinoma. Both ETs,
although smaller in size, showed a higher metastasis rate
than the synchronous metastatic adenocarcinomas.
Discussion
For many years, GIP ETs have been regarded as slow grow-
ing neoplasms with distinct morphologic characteristics
that behave less aggressively than conventional adenocar-
cinomas [1]. The malignant potential of endocrine
tumors is difficult to predict. In this context, the latest
WHO classification provides a useful framework for the
evaluation of clinicopathological and functional proper-
ties of these neoplasms [6]. However, a disadvantage of
the current WHO classification system is that it is not pos-
sible to evaluate some of the well known criteria for
malignancy, namely the presence of metastases, and deep
wall invasion or invasion of nearby tissue in biopsy spec-
imens. Recently, attempts have been made to define his-
tological and immunohistochemical prognostic factors
that may aid in predicting the biologic behavior of GIP
ETs in the context in which they commonly present to the
surgical pathologist. In this context, the study by
Hochwald et al [24] affirmed the clinical usefulness of a
Metastatic, G1 endocrine tumor involving ileal mucosa and  submucosa Figure 1
Metastatic, G1 endocrine tumor involving ileal mucosa and 
submucosa. Note insular growth pattern. Hematoxylin and 
eosin. × 200.
Same tumor as shown in Fig. 1 Figure 2
Same tumor as shown in Fig. 1. Ki-67 monoclonal antibody 
stains nuclei of crypt epithelial and stromal cells. The tumor 
cells are negative. Anti-Ki-67. × 200.
Lymph node metastasis from G1 endocrine tumor as shown  in Fig. 1 Figure 3
Lymph node metastasis from G1 endocrine tumor as shown 
in Fig. 1. Hematoxylin and eosin. × 200.
Lymph node metastasis from G1 endocrine tumor as shown  in Fig. 1 Figure 4
Lymph node metastasis from G1 endocrine tumor as shown 
in Fig. 1. Ki-67 monoclonal antibody stains nuclei of lym-
phocytes. The tumor cells are negative. Anti-Ki-67. × 200.Diagnostic Pathology 2007, 2:28 http://www.diagnosticpathology.org/content/2/1/28
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two-tiered classification of differentiated pancreatic endo-
crine neoplasms into low- and intermediate-grade groups
on the basis of tumor necrosis (absent or present) and
mitotic rate (< 2 mitoses/50 HPFs, or > 2 mitoses/50
HPFs) [24]. Moreover, high-grade ETs were defined as
neoplasms characterized by a solid growth pattern, cyto-
logic atypia, > 10 mitoses/10 HPFs (Ki-67 index > 10%),
and widespread necrosis [6,7,24].
This study investigated the histological grading, Ki-67
index, tumor size, and metastatic behavior in a group of
patients with GIP ETs. The goal was to evaluate Ki-67
index using ChromaVision Automated Image Analysis
software, and to determine whether histological grade,
tumor size, and Ki-67 index had any bearing on metastatic
behavior. We observed unexpectedly high aggressiveness
(multiple lymphogenous and hematogenous metastases,
and peritoneal implants) in small (< 2 cm), low-grade
ETs, with low Ki-67 index. These observations are consist-
ent with other reports [16,18,25]. In his excellent study,
based on analysis of 1914 reported cases with gastrointes-
tinal endocrine tumors, Soga [25] found a high aggressive-
ness in metastasis rates in both rectal and gastric small
carcinoids exhibiting values significantly higher than
Metastatic, G2 endocrine tumor Figure 5
Metastatic, G2 endocrine tumor. Note anisonucleosis and 
focal tumor necrosis. Hematoxylin and eosin. × 400.
Same tumor as shown in Fig. 5 Figure 6
Same tumor as shown in Fig. 5. Only one tumor cell nucleus 
stains positive with Ki-67 monoclonal antibody. Anti-Ki 67. × 
400.
Non-metastatic, G3 endocrine tumor Figure 7
Non-metastatic, G3 endocrine tumor. Hematoxylin and 
eosin. × 400.
Same tumor as shown in Fig. 7 Figure 8
Same tumor as shown in Fig. 7. Numerous tumor cell nuclei 
stain positive with Ki-67 monoclonal antibody. Anti-Ki-67. × 
400.Diagnostic Pathology 2007, 2:28 http://www.diagnosticpathology.org/content/2/1/28
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those of small carcinomas. We did not find statistically
significant correlation between tumor grade and Ki-67
index, as well as between tumor grade, tumor size, Ki-67
index and metastatic behavior of GIP ETs. These observa-
tions are in disagreement with earlier positive findings
[8,11,12,15,19]. This disagreement might be explained by
methodological differences, or the different antibodies
employed. In this context, ChromaVision Automated Ki-
67 index analysis provides superior accuracy in compari-
son to semi quantitative evaluation of Ki-67 positivity.
Most importantly, this study shows the limitations of the
current WHO classification in assessment of the meta-
static behavior of GIP ETs. Thus, we were able to show that
small, low-grade ETs, with low proliferative index, which
met the criteria of the WHO classification criteria for
benignity, behaved in a highly aggressive fashion. On the
other hand large, intermediate- and high-grade, with high
proliferative index ETs, which met the WHO classification
criteria for malignancy, behaved in a benign fashion, i.e.
without metastatic disease. Currently, we cannot explain
the highly aggressive behavior of small, low-grade, with
low proliferative index ETs. Previous studies suggest that
tumors with a short cell cycle may grow rapidly but with-
out necessarily manifesting numerous mitotic figures at
any moment [8]. In addition, recent reports indicate that
nuclear survivin and valosin-containing protein (p97) are
useful prognostic factors in ETs [26,27].
The observed increased risk of synchronous malignancies
in GIP ETs is consistent with previous reports [28-30]. The
results illustrate the need for a thorough search for addi-
tional neoplasms in patients with ileal ETs.
Conclusion
In conclusion, the results suggest that tumor grade does
not significantly correlate with Ki-67 index. Further,
tumor grade, tumor size, and Ki-67 index do not accu-
rately predict malignant behavior of GIP ETs.
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